Currently, there are 60.85M common shares owned by the public and among those 52.66M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -54.46% and -89.66% over the past three months. PLRX shares are trading -89.52% year to date (YTD), with the 12-month market performance down to -91.70% lower. It has a 12-month low price of $2.43 and touched a high of $17.58 over the same period. PLRX has an average intraday trading volume of 1.67 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -72.13%, -85.28%, and -88.52% respectively.
Institutional ownership of Pliant Therapeutics Inc (NASDAQ: PLRX) shares accounts for 97.36% of the company’s 60.85M shares outstanding.
It has a market capitalization of $83.98M and a beta (3y monthly) value of 1.19. The earnings-per-share (ttm) stands at -$3.34. Price movements for the stock have been influenced by the stock’s volatility, which stands at 34.52% over the week and 19.20% over the month.
Earnings per share for the fiscal year are expected to decrease by -5.86%, and 3.10% over the next financial year. EPS should grow at an annualized rate of 5.20% over the next five years, compared to -22.68% over the past 5-year period.
Wells Fargo was of a view on February 10, 2025 that the stock is Equal Weight, while RBC Capital Mkts gave the stock Sector Perform rating on February 10, 2025, issuing a price target of $45- $4. Oppenheimer on their part issued Perform rating on February 10, 2025.
